HC Wainwright Analysts Reduce Earnings Estimates for BHST

BioHarvest Sciences Inc. (NASDAQ:BHST) – Stock analysts at HC Wainwright dropped their Q3 2026 EPS estimates for BioHarvest Sciences in a note issued to investors on Wednesday, August 12th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings per share of ($0.18) for the quarter, down from their previous estimate of ($0.13). The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.41) EPS, FY2028 earnings at ($0.01) EPS, FY2029 earnings at $0.44 EPS and FY2030 earnings at $0.99 EPS.

Other analysts have also recently issued reports about the company. Maxim Group cut their price objective on BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday. Weiss Ratings upgraded BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. Finally, Roth Capital dropped their price target on shares of BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $6.50.

BioHarvest Sciences Stock Performance

Shares of BHST stock opened at $2.07 on Friday. The company has a market capitalization of $40.61 million, a P/E ratio of -3.98 and a beta of 0.97. The business’s 50 day moving average is $2.68 and its two-hundred day moving average is $3.75. The company has a current ratio of 2.96, a quick ratio of 2.44 and a debt-to-equity ratio of 0.03. BioHarvest Sciences has a 12-month low of $1.82 and a 12-month high of $12.80.

BioHarvest Sciences (NASDAQ:BHST) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04). BioHarvest Sciences had a negative return on equity of 59.10% and a negative net margin of 31.21%.The firm had revenue of $8.84 million during the quarter, compared to analyst estimates of $9.45 million.

Institutional Trading of BioHarvest Sciences

Several large investors have recently made changes to their positions in BHST. Virtu Financial LLC purchased a new position in BioHarvest Sciences in the 4th quarter valued at $60,000. Geode Capital Management LLC acquired a new position in BioHarvest Sciences during the fourth quarter worth about $61,000. HRT Financial LP purchased a new stake in BioHarvest Sciences during the 4th quarter valued at about $75,000. Marshall Wace LLP acquired a new stake in BioHarvest Sciences in the 4th quarter valued at about $110,000. Finally, Silverberg Bernstein Capital Management LLC acquired a new position in shares of BioHarvest Sciences during the 1st quarter worth approximately $113,000.

Key BioHarvest Sciences News

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: Maxim Group reaffirmed its “Buy” rating on BioHarvest Sciences, signaling continued confidence in the company’s long-term growth prospects. Maxim Group Reaffirms Their Buy Rating on BioHarvest Sciences
• Positive Sentiment: Roth Capital kept a “Buy” rating despite reducing its price target from $10 to $8. The revised target still implies substantial potential upside from the recent $2.07 share price, provided the company can execute on its growth plans. Roth Capital Lowers BioHarvest Sciences Price Target
• Neutral Sentiment: BioHarvest Sciences’ Q2 2026 earnings-call transcript is available, offering investors additional commentary on operating performance, commercialization, and management’s outlook. BioHarvest Sciences Q2 2026 Earnings Call Transcript
• Negative Sentiment: HC Wainwright reduced EPS forecasts across 2026–2030. Estimates were lowered to losses of $0.18 per share for Q3 2026, $0.15 for Q4, and $0.59 for full-year 2026. Forecast losses also increased for 2027 and 2028, while projected profit for 2029 and 2030 was cut to $0.44 and $0.99 per share, respectively. The broad revisions suggest slower profitability and weaker near-term expectations.
• Negative Sentiment: The estimate cuts add to concerns following BioHarvest Sciences’ recent quarterly results, when revenue and EPS fell short of analyst expectations. The company remains unprofitable, increasing the sensitivity of its stock to execution and financing risks.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.